Briacell Therapeutics Corp (BCTX)

$3.96 +0.43 (12.18%)
Market Cap 29.49M
Revenue (ttm) 0.00
Net Income (ttm) -26.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 314,008
Avg Vol 139,788
Day's Range N/A - N/A
Shares Out 8.70M
Stochastic %K 53%
Beta 1.14
Analysts Strong Buy
Price Target $40.00

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 921 1810
Fax: 604 921 1898
Address:
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada
dlev18
dlev18 Aug. 19 at 8:40 PM
$BCTX people think we’re a bitcoin stock or are we actually showing momentum???
0 · Reply
durocali
durocali Aug. 19 at 7:58 PM
$BCTX lucky to be able to add @ $3.40 this week. market may sense a bit more validation around the potential for Bria-IMT favorable topline data to come this 2H2026... with nice sympathy move up today on heels of $MRK and $MRNA news. countdown to readout ticking louder...
0 · Reply
rp6577
rp6577 Aug. 19 at 7:20 PM
$BCTX heating up $XBI
0 · Reply
Stonehands
Stonehands Aug. 19 at 7:18 PM
$BCTX hmmm
0 · Reply
tbagoni
tbagoni Aug. 19 at 7:13 PM
$BCTX $BCTX $4
0 · Reply
tname
tname Aug. 19 at 7:11 PM
$BCTX 🚀
0 · Reply
Kirubin
Kirubin Aug. 19 at 7:01 PM
$BCTX okay! Started with 11K this morning! Just to nibble at it! Gamble gable! Price has stabilized! sell order at $120🫢🤦🏽‍♂️
2 · Reply
smallpower17
smallpower17 Aug. 19 at 6:31 PM
$BCTX Since there are no good other options for metastatic breast cancer, the other options have horrible side effects, the BriaCell therapy has shown no side effects, and the Phase 3 trial results will be categorized into several different patient subgroups, there are several paths for full approval (each of the patient subgroups - patients with intracranial disease, as just one example).
0 · Reply
BCTX20bMC
BCTX20bMC Aug. 19 at 4:56 PM
$BCTX wake me up at $300
1 · Reply
rp6577
rp6577 Aug. 19 at 4:37 PM
$BCTX looking for that $4 break
1 · Reply
Latest News on BCTX
BriaCell gets FDA clearance for Bria-PROS+ study in prostate cancer

2026-08-05T13:46:04.000Z - 14 days ago

BriaCell gets FDA clearance for Bria-PROS+ study in prostate cancer

BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer

Wed, 05 Aug 2026 07:30:00 -0400 - 14 days ago

BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer

BriaCell (BCTX) Expands Phase 3 Study with New Clinical Site

2026-07-16T13:27:49.000Z - 4 weeks ago

BriaCell (BCTX) Expands Phase 3 Study with New Clinical Site

BriaCell announces Odette Cancer Centre joins Bria-IMT trial

2026-07-16T11:40:48.000Z - 4 weeks ago

BriaCell announces Odette Cancer Centre joins Bria-IMT trial

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

Thu, 16 Jul 2026 07:30:00 -0400 - 4 weeks ago

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell (BCTX) Partners with Fujifilm for Cell Therapy Manufacturing

2026-07-15T13:32:56.000Z - 5 weeks ago

BriaCell (BCTX) Partners with Fujifilm for Cell Therapy Manufacturing

BriaCell arranges scalable manufacturing with Fujifilm Biotechnologies

2026-07-15T12:10:22.000Z - 5 weeks ago

BriaCell arranges scalable manufacturing with Fujifilm Biotechnologies

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

Wed, 15 Jul 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

Tue, 07 Jul 2026 07:30:00 -0400 - 6 weeks ago

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

2026-06-26T10:06:07.000Z - 7 weeks ago

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

2026-06-25T13:25:58.000Z - 7 weeks ago

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

BriaCell enters MoU with Uneedle for microneedle technology

2026-06-25T11:45:30.000Z - 7 weeks ago

BriaCell enters MoU with Uneedle for microneedle technology

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

Thu, 25 Jun 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

BriaCell Therapeutics Announces Closing of Offering

Tue, 02 Jun 2026 16:05:00 -0400 - 2 months ago

BriaCell Therapeutics Announces Closing of Offering

BriaCell Presents Positive Clinical Data at ASCO 2026

Mon, 01 Jun 2026 07:30:00 -0400 - 2 months ago

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics Announces Pricing of Offering

Sun, 31 May 2026 19:59:00 -0400 - 2 months ago

BriaCell Therapeutics Announces Pricing of Offering

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

2026-05-26T14:43:01.000Z - 3 months ago

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

2026-05-26T13:05:39.000Z - 3 months ago

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Tue, 26 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T13:27:19.000Z - 3 months ago

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

BriaCell announces data from Bria-IMT at ASCO 2026

2026-05-22T11:49:02.000Z - 3 months ago

BriaCell announces data from Bria-IMT at ASCO 2026

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

Fri, 15 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

2026-05-14T15:31:53.000Z - 3 months ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

Thu, 14 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T16:39:28.000Z - 3 months ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

2026-05-13T14:41:55.000Z - 3 months ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Wed, 13 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Tue, 12 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Thu, 07 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

2026-05-07T04:03:56.000Z - 3 months ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Wed, 06 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

Mon, 27 Apr 2026 07:30:00 -0400 - 4 months ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T13:28:43.000Z - 4 months ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

BriaCell presents anti-cancer activity of Bria-OTS

2026-04-21T11:54:23.000Z - 4 months ago

BriaCell presents anti-cancer activity of Bria-OTS

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

Tue, 21 Apr 2026 07:30:00 -0400 - 4 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T13:32:04.000Z - 4 months ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

2026-04-20T11:41:56.000Z - 4 months ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Mon, 20 Apr 2026 07:30:00 -0400 - 4 months ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

Tue, 31 Mar 2026 16:05:00 -0400 - 5 months ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T13:30:56.000Z - 5 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

BriaCell to present four posters at the 2026 AACR

2026-03-18T11:42:55.000Z - 5 months ago

BriaCell to present four posters at the 2026 AACR

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Wed, 18 Mar 2026 07:30:00 -0400 - 5 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Tue, 10 Mar 2026 07:30:00 -0400 - 5 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 5 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:51:30.000Z - 6 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

2026-02-18T22:35:25.000Z - 6 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

Wed, 18 Feb 2026 17:30:00 -0500 - 6 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

2026-02-17T12:40:59.000Z - 6 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Tue, 17 Feb 2026 07:30:00 -0500 - 6 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell says patient images show regression, resolution of metastsized tumors

2026-01-28T12:40:40.000Z - 7 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Jan 28, 2026, 7:30 AM EST - 7 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

2026-01-27T12:41:04.000Z - 7 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Jan 27, 2026, 7:30 AM EST - 7 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Jan 15, 2026, 4:05 PM EST - 7 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

Jan 13, 2026, 9:00 PM EST - 7 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

BriaCell Therapeutics trading resumes

2026-01-13T14:41:11.000Z - 7 months ago

BriaCell Therapeutics trading resumes

BriaCell Therapeutics trading halted, volatility trading pause

2026-01-13T14:35:29.000Z - 7 months ago

BriaCell Therapeutics trading halted, volatility trading pause

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

2026-01-13T12:35:49.000Z - 7 months ago

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Jan 13, 2026, 7:30 AM EST - 7 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Dec 18, 2025, 7:30 AM EST - 8 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

BriaCell presents Phase 2, Phase 3 data on Bria-IMT at SABCS 2025

2025-12-10T12:41:29.000Z - 9 months ago

BriaCell presents Phase 2, Phase 3 data on Bria-IMT at SABCS 2025

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Dec 10, 2025, 7:30 AM EST - 9 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Dec 9, 2025, 7:30 AM EST - 9 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Dec 2, 2025, 7:30 AM EST - 9 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 9 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 20, 2025, 7:30 AM EST - 9 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 18, 2025, 7:30 AM EST - 9 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 7, 2025, 7:30 AM EST - 10 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Nov 4, 2025, 7:30 AM EST - 10 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:50 AM EDT - 10 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 21, 2025, 7:30 AM EDT - 10 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 20, 2025, 7:30 AM EDT - 10 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 11 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Oct 3, 2025, 7:30 AM EDT - 11 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 26, 2025, 7:30 AM EDT - 1 year ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 25, 2025, 7:30 AM EDT - 1 year ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 21, 2025, 12:00 PM EDT - 1 year ago

BriaCell Announces Proposed Effective Date of Share Consolidation

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Aug 13, 2025, 7:30 AM EDT - 1 year ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 31, 2025, 7:30 AM EDT - 1 year ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 30, 2025, 7:30 AM EDT - 1 year ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 29, 2025, 7:30 AM EDT - 1 year ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

dlev18
dlev18 Aug. 19 at 8:40 PM
$BCTX people think we’re a bitcoin stock or are we actually showing momentum???
0 · Reply
durocali
durocali Aug. 19 at 7:58 PM
$BCTX lucky to be able to add @ $3.40 this week. market may sense a bit more validation around the potential for Bria-IMT favorable topline data to come this 2H2026... with nice sympathy move up today on heels of $MRK and $MRNA news. countdown to readout ticking louder...
0 · Reply
rp6577
rp6577 Aug. 19 at 7:20 PM
$BCTX heating up $XBI
0 · Reply
Stonehands
Stonehands Aug. 19 at 7:18 PM
$BCTX hmmm
0 · Reply
tbagoni
tbagoni Aug. 19 at 7:13 PM
$BCTX $BCTX $4
0 · Reply
tname
tname Aug. 19 at 7:11 PM
$BCTX 🚀
0 · Reply
Kirubin
Kirubin Aug. 19 at 7:01 PM
$BCTX okay! Started with 11K this morning! Just to nibble at it! Gamble gable! Price has stabilized! sell order at $120🫢🤦🏽‍♂️
2 · Reply
smallpower17
smallpower17 Aug. 19 at 6:31 PM
$BCTX Since there are no good other options for metastatic breast cancer, the other options have horrible side effects, the BriaCell therapy has shown no side effects, and the Phase 3 trial results will be categorized into several different patient subgroups, there are several paths for full approval (each of the patient subgroups - patients with intracranial disease, as just one example).
0 · Reply
BCTX20bMC
BCTX20bMC Aug. 19 at 4:56 PM
$BCTX wake me up at $300
1 · Reply
rp6577
rp6577 Aug. 19 at 4:37 PM
$BCTX looking for that $4 break
1 · Reply
AliceFireSteam
AliceFireSteam Aug. 19 at 2:44 PM
$BCTX Merck and Moderna have just released data on a cancer vaccine. Personalized patient-by-patient Cpi+Intismeran, slow, expensive but it works, only helps to prove the Briacell method. Bristol Myers Squibb, 11B in the vault, with no current competition against this vaccine... Buyout probably?
2 · Reply
jfun1
jfun1 Aug. 19 at 2:29 PM
$BCTX Definitely eyes on the vaccines for cancer treatments. Great for humanity if they work
0 · Reply
Kirubin
Kirubin Aug. 19 at 2:08 PM
$BCTX okay🫡🫢
0 · Reply
letsdodiz
letsdodiz Aug. 19 at 2:01 PM
$BCTX volume is picking up . Looks like we are getting some vibes from Moderna news. I bought some Moderna in the 20s and sold in the 50s.🥲
1 · Reply
Ares77manoe
Ares77manoe Aug. 19 at 1:57 PM
$BCTX nice
0 · Reply
AliceFireSteam
AliceFireSteam Aug. 19 at 4:12 AM
$BCTX https://www.researchgate.net/scientific-contributions/William-Williams-2142334235 for those that want the underlying data (paid)
1 · Reply
USAEquityResearch
USAEquityResearch Aug. 19 at 12:03 AM
$BCTX 📊 USAEquityResearch ▲ 3.53 (+4.13%) Trend: Bullish 📈 RSI (14): 52.0 — neutral territory MACD: bearish, below signal line Volume: below average 📌 Key Levels Resistance: 3.73 Support: 3.36 20-MA: 3.51 | 50-MA: 3.34 Educational content only. Not financial advice.
0 · Reply
NoFooling
NoFooling Aug. 18 at 6:49 PM
$BCTX watch RENMARK PRESENTATION of June 25, 2026 especially the Q&A: Best case scenario is 144th death occurs in December = Survival Readout exceeds anticipated successful June Conclusion by 6 months. https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-06-25-11-00-00/index.html
3 · Reply
smallpower17
smallpower17 Aug. 18 at 5:08 PM
$BCTX Rumors of great trial results leaking out??
1 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 7:46 PM
$CIIT $DCOY $BCTX $INTJ $NAAS nice
0 · Reply
AliceFireSteam
AliceFireSteam Aug. 17 at 9:25 AM
$BCTX per the sec filling of the last offering with ThinkEquity they are blocked from new offerings until September.
0 · Reply
BHWinehouse
BHWinehouse Aug. 16 at 8:28 PM
$BCTX Fun fact: Our CRO, Prevail InfoWorks, not only is our CRO but, at the time, also "saw something" that compelled them to invest in BCTX via their investment arm Prevail Partners at a 20% premium.
0 · Reply